



**HAL**  
open science

## Commercially available tests for determining cefiderocol susceptibility display variable performance in the *Achromobacter* genus

Vincent Jean-Pierre, Pauline Sorlin, Katy Jeannot, Raphaël Chiron, Jean-Philippe Lavigne, Alix Pantel, H. Marchandin

### ► To cite this version:

Vincent Jean-Pierre, Pauline Sorlin, Katy Jeannot, Raphaël Chiron, Jean-Philippe Lavigne, et al.. Commercially available tests for determining cefiderocol susceptibility display variable performance in the *Achromobacter* genus. *Annals of Clinical Microbiology and Antimicrobials*, 2024, 23 (1), pp.78. 10.1186/s12941-024-00731-1 . hal-04873210

**HAL Id: hal-04873210**

<https://hal.science/hal-04873210v1>

Submitted on 8 Jan 2025

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

RESEARCH

Open Access



# Commercially available tests for determining cefiderocol susceptibility display variable performance in the *Achromobacter* genus

Vincent Jean-Pierre<sup>1</sup>, Pauline Sorlin<sup>2</sup>, Katy Jeannot<sup>3</sup>, Raphaël Chiron<sup>4</sup>, Jean-Philippe Lavigne<sup>5</sup>, Alix Pantel<sup>5</sup> and H  l  ne Marchandin<sup>1\*</sup>

## Abstract

**Background** Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of *Achromobacter* infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the pathogens.

**Objectives** We evaluated the performance of commercial tests for testing cefiderocol susceptibility in the *Achromobacter* genus and reviewed the literature.

**Methods** Diffusion (disks, MIC gradient test strips [MTS], Liofilchem) and broth microdilution (BMD) methods (ComASP<sup>TM</sup>, Liofilchem; UMIC<sup> </sup>, Bruker) were compared with the BMD reference method according to the EUCAST guidelines on 143 *Achromobacter* strains from 14 species with MIC<sub>50/90</sub> of  $\leq 0.015/0.5$  mg/L. A literature search was conducted regardless of method or species.

**Results** None of the methods tested fulfilled an acceptable essential agreement (EA). MTS displayed the lowest EA (30.8%) after UMIC<sup> </sup> (49%) and ComASP<sup>TM</sup> (76.9%). All methods achieved an acceptable bias, with MICs either underestimated using MTS (-1.3%) and ComASP<sup>TM</sup> (-14.2%) or overestimated with UMIC<sup> </sup> (+9.1%). Inhibition zone diameters ranged from 6 to 38 mm (IZD<sub>50/90</sub>=33/30 mm). UMIC<sup> </sup> and ComASP<sup>TM</sup> failed to categorize one or the two cefiderocol-resistant strains of this study as resistant unlike the diffusion-based methods. The literature review highlighted distinct performance of the available methods according to pathogens and testing conditions.

**Conclusions** The use of MTS is discouraged for *Achromobacter* spp. Disk diffusion can be used to screen for susceptible strains by setting a threshold diameter of 30 mm. UMIC<sup> </sup> and ComASP<sup>TM</sup> should not be used as the sole method but have to be systematically associated with disk diffusion to detect the yet rarely described cefiderocol-resistant *Achromobacter* sp. strains.

Part of this work was presented at the 33<sup>rd</sup> European Congress of Clinical Microbiology and Infectious Diseases, April 15<sup>th</sup>–18<sup>th</sup> 2023, Copenhagen, Denmark and at the 46<sup>th</sup> European Cystic Fibrosis Conference, June 7<sup>th</sup>–10<sup>th</sup> 2023, Vienna, Austria.

\*Correspondence:  
H  l  ne Marchandin  
helene.marchandin@umontpellier.fr

Full list of author information is available at the end of the article



   The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

## Highlights

- Performance of commercial methods are highly diverse and species-dependent.
- The use of MTS is discouraged due to low essential agreement.
- UMIC<sup>®</sup> and ComASP<sup>™</sup> failed to detect one or the two cefiderocol-resistant strains.
- UMIC<sup>®</sup> or ComASP<sup>™</sup> should not be used as the sole method for *Achromobacter* cefiderocol susceptibility testing.
- A threshold diameter of 30 mm is proposed for susceptible strain screening.

**Keywords** Cefiderocol, *Achromobacter*, Susceptibility testing, Microdilution, Disk, Diffusion

## Introduction

*Achromobacter* spp. are recognized as opportunistic pathogens, predominantly infecting immunocompromised individuals and patients with cystic fibrosis (CF). These microorganisms are often considered as difficult-to-treat pathogens due to their intrinsic antimicrobial resistance and potential acquisition of additional resistances [1, 2]. Cefiderocol is a broad-spectrum siderophore cephalosporin increasingly used in the management of *Achromobacter* infections [2–5]. Considering studies which determined minimal inhibitory concentrations (MICs) using the broth microdilution (BMD) reference method according to the EUCAST (European committee on antimicrobial susceptibility testing) guidelines, cefiderocol was shown to have excellent in vitro activity against *Achromobacter* spp. In total, according to the EUCAST 2023 non-species-related breakpoint (2 mg/L), only 2.1% (13/606) of strains were resistant to cefiderocol [6–10] with MIC<sub>50</sub> values ranging from ≤0.015 mg/L [6] to 0.5 mg/L [7], and MIC<sub>90</sub> values ranging from 0.125 mg/L [8] to 1 mg/L [7].

However, the BMD reference method, which is based on iron-depleted-cation-adjusted Mueller-Hinton broth (ID-CAMHB), is complex, time-consuming, and therefore difficult to apply routinely in a clinical microbiology laboratory for in vitro susceptibility testing of cefiderocol [11]. Consequently, more widely accessible antimicrobial susceptibility testing (AST) methods have been developed for routine cefiderocol susceptibility tests, such as the disk diffusion method, cefiderocol-impregnated strips, both tested on regular Mueller-Hinton-agar (r-MHA), and several microdilution panels. To date, the recommendations for use of these different methods vary depending on the antibiogram committee or regulatory agency and the bacterial species under consideration, and so do the breakpoints applied for categorization (Table 1). In the absence of specific recommendations for *Achromobacter* spp., the most accurate method to be used for cefiderocol susceptibility testing of *Achromobacter* spp. strains can therefore not be inferred from the current recommendations published for other opportunistic pathogens and thus warranted a specific evaluation.

In this study, commercialized BMD methods, *i.e.*, the compact antimicrobial susceptibility panel (ComASP<sup>™</sup>) microdilution assay (Liofilchem, Roseto degli Abruzzi, Teramo, Italy) and UMIC<sup>®</sup> (Bruker Daltonics GmbH & Co. KG, Bremen, Germany), MIC gradient test strips (MTS) and disks (Liofilchem) were compared with the previous results we obtained with the BMD reference method on a collection of *Achromobacter* spp. clinical isolates accurately identified by *nrdA* gene-based analysis [6]. Our goal was to identify the most accurate commercial method for testing *Achromobacter* spp. Specifically, for disk diffusion, we aimed to determine an inhibition zone diameter (IZD) threshold that might be helpful for distinguishing susceptible *Achromobacter* strains from strains with abnormal susceptibility that would require further testing. Finally, we conducted a literature review to summarize the data on methods that displayed the best performance for cefiderocol susceptibility testing according to bacterial species and compared the results with those of the evaluation conducted on *Achromobacter* spp. herein.

## Materials and methods

### Bacterial isolates

#### *Achromobacter* spp. collection beyond study

A collection of 143 clinically-documented strains of *Achromobacter* spp., representing a subgroup of the 230 strains previously described by Jean-Pierre et al., was selected for this study [6] (Supplementary Table 1). The collection included 67 strains from 67 CF patients and 76 strains from 76 non-CF (NCF) patients. These strains were isolated between 2010 and 2023 during routine microbiological analysis of samples from patients attending CF centres (CRCM, Centre de Ressource et de Compétence de la Mucoviscidose) of the University Hospitals of Paris, Montpellier (France) and Aarhus (Denmark), and at the University Hospitals of Montpellier and Nîmes, and Hospital of Alès-Cévennes (France) for NCF patients. Most strains originated from the respiratory tract, 100% of CF strains (67/67) and 39.5% of NCF strains (30/76), followed by blood cultures (18.4% of NCF strains, 14/76) and ear-nose-throat samples (15.8% of NCF strains, 12/76) and various other sources including skin wounds and pus, biopsies, the digestive tract,

**Table 1** Clinical breakpoints for ceftiderocol published by antibiogram committees and/or regulatory agencies in 2024

Microorganism and non-species related PK/PD breakpoints	CA-SFM			EUCAST			CLSI			FDA		
	MIC, mg/L	IZD, mm <sup>a</sup>	ATU	MIC, mg/L	IZD, mm <sup>a</sup>	ATU	MIC, mg/L	IZD, mm <sup>a</sup>	MIC, mg/L	IZD, mm <sup>a</sup>	MIC, mg/L	IZD, mm <sup>a</sup>
	≤ S	> R	≥ S	≤ S	> R	≥ S	≤ S	> R	≤ S	> R	≤ S	> R
Enterobacterales	2	2	-	2	2	21–23	4	16	4	16	4	16
<i>Pseudomonas aeruginosa</i>	2	2	27	2	2	<27	4	16	1	12	1	4
<i>Acinetobacter baumannii</i> complex	IE	IE	<sup>b</sup>	IE	IE	-	4	16	1	15 <sup>f</sup>	1	4
<i>Stenotrophomonas maltophilia</i>	IE	IE	<sup>c</sup>	IE	IE	-	1	-	-	15 <sup>g</sup>	-	-
PK/PD	2	2	-	-	-	-	-	-	-	-	-	-

Abbreviations: ATU: area of technical uncertainty; CA-SFM: Antibiogram Committee of the French Society of Microbiology; CLSI: Clinical & Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; FDA: Food and Drug Administration; IE: insufficient evidence; IZD: inhibition zone diameter; MIC: minimal inhibitory concentration; PK/PD: pharmacokinetics and pharmacodynamics; R: resistant; S: susceptible

<sup>a</sup>30 µg disk content

<sup>b</sup>IZD of ≥ 22 mm for the ceftiderocol 30 µg disk correspond to MIC values below the PK/PD breakpoint of S ≤ 2 mg/L

<sup>c</sup>IZD of ≥ 20 mm for the ceftiderocol 30 µg disk correspond to MIC values below the PK/PD breakpoint of S ≤ 2 mg/L

<sup>d</sup>IZD of ≥ 17 mm for the ceftiderocol 30 µg disk correspond to MIC values below the PK/PD breakpoint of S ≤ 2 mg/L

<sup>e</sup>IZD of ≥ 20 mm for the ceftiderocol 30 µg disk correspond to MIC values below the PK/PD breakpoint of S ≤ 2 mg/L

<sup>f</sup>Disk diffusion diameters ≤ 14 mm should not be interpreted or reported because IZD ≤ 14 mm occur with resistant, intermediate and susceptible isolates. For isolates with IZD ≤ 14 mm, do not report ceftiderocol without performing an MIC test

<sup>g</sup>Breakpoints are based on PK/PD properties, and limited clinical data

implantable devices, and eyes (26.3% of NCF strains, 20/76). These strains had been identified in a previous study by *nrdA* gene sequencing (765 bp), analysis, and phylogeny [12]. Strains beyond study were genetically diverse, displaying 50 alleles of the *nrdA* gene and were assigned to 14 species of the *Achromobacter* genus. *Achromobacter xylosoxidans* and 13 other species represented 65% (93/143) and 35% (50/143) of strains, respectively. Among the 143 strains, most isolates were susceptible to meropenem (MEM) (87.4%, 125/143), piperacillin-tazobactam (TZP) (86.7%, 124/143) and trimethoprim-sulfamethoxazole (SXT) (81.1%, 116/143), applying the IZD breakpoints of *A. xylosoxidans* to all *Achromobacter* species [13]. Reference ceftiderocol MIC values were determined by the National Reference Centre for Antibiotic Resistance (Besançon, France) using an ID-CAMHB as described by Devoos et al. [14] and ranged from ≤ 0.015 to 16 mg/L (MIC<sub>50/90</sub> of 0.03/0.5 mg/L overall and 0.125/2 mg/L against MEM non-susceptible strains). In total, 141 strains (98.6%) were susceptible (MIC ≤ 2 mg/L) and two strains were resistant to ceftiderocol (MIC > 2 mg/L) according to the EUCAST 2023 non-species-related breakpoint (Supplementary Table 1) [15]. All strains were stored frozen at -80 °C in glycerol Trypticase-soy broth.

#### Quality control strain

Quality control using *Pseudomonas aeruginosa* strain CIP 76110 (= ATCC 27853) was included in each series of BMD, ComASP™, and UMIC®, and five series of MTS and disk diffusion to ensure the validity of methods, checking that the results were within the specified range: 0.06 to 0.5 mg/L (for MIC determination) and 23 to 29 mm (for IZD determination) according to EUCAST recommendations [13].

#### Commercial AST of ceftiderocol of *Achromobacter* spp.

All tests were performed from overnight cultures on Difco™ r-MHA plates (Becton Dickinson) at 35–37 °C for 18–24 h (unless additional incubation was required to achieve sufficient growth). A bacterial suspension adjusted to 0.5 McFarland in 0.9% sodium chloride solution was used for the four methods in this study. All tests were performed according to both the manufacturer's recommendations and the EUCAST guidelines, and results were compared with those of the BMD reference method. Clinical breakpoints used for ceftiderocol results interpretation were EUCAST 2023 non-species-related pharmacokinetic/pharmacodynamic (PK/PD) values (susceptible strain: MIC ≤ 2 mg/L; resistant strain: MIC > 2 mg/L) [15]. At that point, no IZD breakpoints had been defined for *Achromobacter* spp. and ceftiderocol. Both IZD and MIC values were determined separately by

two operators, and by a third operator if there was any disagreement.

#### **Commercial diffusion methods: disk diffusion and MTS**

Cefiderocol disk diffusion assays were performed with disks loaded at 30 µg (Liofilchem). Cefiderocol MTS assays (Liofilchem) generate a range of concentrations from 0.016 to 256 mg/L and are only validated and approved for *P. aeruginosa*. Both disk and MTS assays were tested on unsupplemented MH II agar plates (Liofilchem). Colonies within the inhibition zones were considered after excluding any possible contamination, according to the EUCAST recommendations [13].

#### **Commercial BMD methods: ComASP™ and UMIC®**

The ComASP™ microdilution assay (Liofilchem) is a two-test panel using an iron-depleted MH broth supplied in the kit, generating a range of concentrations from 0.008 to 128 mg/L. The UMIC® assay (Bruker Daltonics GmbH & Co. KG, Bremen, Germany) is a unit test that uses iron-depleted MH broth, which is not supplied in the kit, generating a range of concentrations from 0.03 to 32 mg/L. Both tests were used according to the manufacturer's instructions. Briefly, for ComASP™, the bacterial suspension was diluted to 1:20 and 0.4 mL of this suspension was used to inoculate ID-CAMHB (3.6 mL). Next, 100 µL were dispensed into each well followed by 16–20 h of incubation at 35–37 °C under aerobic conditions. For UMIC®, a volume of 25 µL of the bacterial suspension was used to inoculate ID-CAMHB (5 mL) and 100 µL were dispensed into each well of the strip followed by 18–24 h of incubation at 35–37 °C under aerobic conditions. For both commercial BMD methods, the MIC of cefiderocol was then read as the first well in which the growth reduction corresponded to a dot of <1 mm or was replaced by the presence of light haze/faint turbidity according to the recommendations [11]. The positive control should show strong growth in the form of a dot of >2 mm or heavy turbidity. If considerable growth was not observed in the growth control well, the panels were incubated for a further incubation period.

#### **Literature review**

A literature search was conducted using the PubMed database, with the last search date being June 18th, 2024. The search was performed using a combination of Mesh terms: “disk or disc” and/or “MTS” and/or “ComASP” and/or “UMIC” and/or “Sensititre” and “cefiderocol”, and followed by manual selection of studies that had made a comparative analysis of the performance of different methods for cefiderocol susceptibility testing. Of the 49 studies that were identified and screened, 33 were excluded because they did not involve a comparison of the performance of a commercial test with a BMD

method, and 16 were included in the review. The results were aggregated according to species or bacterial group and were then used to compare the results of our evaluation on *Achromobacter* spp.

#### **Data analysis and interpretation**

Essential agreement (EA), inferior and superior bias were calculated according to ISO 20776-2:2021 guidelines, with the BMD method and EUCAST 2023 PK/PD breakpoints as references [15, 16]. Percentages ≥90% for EA, and a difference for bias ±30% were considered as acceptable [16]. These criteria were also those applied to evaluate the performance of studies retrieved from our literature review. The ISO 20776-2:2007 guidelines require 10% of resistant strains for the whole study before categorical agreement (CA), major errors (ME) and very major errors (VME) can be calculated [17]. The small number of resistant strains included in this study ( $n=2$ ) and, more largely, the small number of cefiderocol-resistant *Achromobacter* strains reported in the literature thus avoided calculating CA, ME and VME in this genus. The generally acceptable criteria considered for evaluating the performance of the studies retrieved from our literature review were: CA >90%, ME rate <3% of the susceptible isolates tested, and a lower rate of VME <1.5% of the resistant isolates according to the FDA.


Statistical analysis of discrepancies in MICs between commercial tests and the BMD reference method were performed using the Fisher test with GraphPad Prism (GraphPad Software, La Jolla, CA). A two-tailed  $p$ -value <0.05 was chosen as being statistically significant.

## **Results**

#### **Commercial BMD methods: ComASP™ and UMIC®**

The MIC values of cefiderocol for the quality control strain *P. aeruginosa* CIP 76110 with both BMD tests (range<sub>ComASP™</sub>: 0.064–0.25 mg/L,  $n=23$ ; range<sub>UMIC®</sub>: 0.125–0.5 mg/L,  $n=5$ ) were within the acceptable range although ComASP™ and UMIC® tended to result in MIC respectively lower and higher than the target values (Supplementary Fig. 1).

Compared with the BMD reference method, neither the ComASP™ nor the UMIC® methods achieved an acceptable 90% EA rate (EA = 76.9%,  $n=110/143$ , 95% CI [69.4–83.1] for ComASP™ and EA = 49%,  $n=70/143$ , 95% CI [40.9–57.1] for UMIC®) (Fig. 1; Table 2). EAs reached the 90% rate for both techniques only when a difference from the reference method of ±three 2-fold dilutions was considered (modified EA<sub>ComASP™</sub> = 97.2%,  $n=139/143$ , 95% CI [93–98.9] and modified EA<sub>UMIC®</sub> = 92.3%,  $n=132/143$ , 95% CI [86.7–95.6]). Although the ComASP™ test tended to provide lower MIC values, as illustrated by a negative bias (-14.2%), the UMIC® tended to provide higher MIC values (bias = +9.1%), compared to the BMD reference



**Fig. 1** Correlation between cefiderocol MICs determined by the reference BMD method and by commercial methods (a) ComASP™, (b) UMIC® and (c) MTS. MTS assays were performed on unsupplemented MH II agar plates (Liofilchem). The number of strains with MIC determined by the commercial method corresponding to the BMD method,  $\pm 1$  two-fold dilution,  $\pm 2$  two-fold dilution,  $\pm 3$  two-fold dilution and  $\geq \pm 4$  two-fold dilution compared to the reference MIC, are highlighted in dark grey, light grey, light orange, dark orange and white areas, respectively. BMD: broth microdilution; MIC: minimal inhibitory concentration.

**Table 2** Performance of ComASP™, UMIC®, Liofilchem MTS and disk tested on unsupplemented MH II agar plates (Liofilchem) for the determination of susceptibility to cefiderocol of 143 *Achromobacter* spp. clinical isolates according to EUCAST PK/PD breakpoint in comparison with BMD reference method

Method	MIC (mg/L) or IZD (mm) range	MIC <sub>50</sub> (mg/L) or IZD <sub>50</sub> (mm)	MIC <sub>90</sub> (mg/L) or IZD <sub>90</sub> (mm)	EA	Bias high	Bias low	Difference of bias	Number of resistant strains detected (n=2)
BMD	$\leq 0.015$ to 16	0.03	0.5	-	-	-	-	-
ComASP™*	$\leq 0.016$ to 2	0.032	0.25	76.9 (110)	+46.1 (66/143)	-60.3 (47/78)	-14.2	0
UMIC®**	$\leq 0.03$ to 4	0.125	0.5	49 (70)	+47.6 (68/143)	-38.5 (30/78)	+9.1	1
MTS*	$\leq 0.016$ to > 256	0.064	0.38	30.8 (44)	+53.8 (77/143)	-55.1 (43/78)	-1.3	2
Disk diffusion**	39 to 6	33	30	-	-	-	-	2

BMD: broth microdilution; EA: essential agreement; IZD: inhibition zone diameter; MIC: minimal inhibitory concentration; -: not applicable

As there are no specific indications for this genus: \*MIC were interpreted according to the EUCAST 2023 PK/PD breakpoints, \*\*IZD were interpreted according to *P. aeruginosa*-specific breakpoints. In accordance with ISO 20776-2:2021, the acceptable rates are indicated in bold (EA  $\geq 90\%$ , and difference of bias low and high  $\pm 30\%$ )

method, as also observed for the quality control strain (Fig. 1; Table 2, Supplementary Fig. 1, Supplementary Table 2).

Of the two strains 2579 and 2463, classified as resistant to cefiderocol with MIC values of 16 mg/L using the BMD reference method, strain 2579 was wrongly categorized as susceptible with both ComASP™ and UMIC® with MIC values of 0.125 mg/L, far from the reference value, whereas strain 2463 was wrongly categorized as susceptible with ComASP™ alone, with an MIC of 2 mg/L, close to the EUCAST 2023 PK/PD breakpoint [15] (Supplementary Table 1).

**Commercial diffusion methods: disk diffusion and MTS**  
**Disk diffusion**

IZDs for the *P. aeruginosa* quality control strain (range: 26–27 mm, n=5) were all within the acceptable range (23–29 mm) and met the acceptability criteria ( $\pm 1$  mm from the target value) defined by the EUCAST in its warning published in August 2022 [18].

IZD varied greatly for a same MIC: for strains with a reference MIC  $\leq 0.015$  mg/L (n=65), IZD ranged from 27 mm to 38 mm overall (IZD<sub>50/90</sub> = 34/31 mm) and from 27 mm to 37 mm (IZD<sub>50/90</sub> = 30/27 mm) for strains with a reference MIC of 2 mg/L (n=5), suggesting that the

disk diffusion method did not correlate very well with the BMD reference method (Supplementary Fig. 2). However, the only two strains resistant to cefiderocol with the BMD reference method (strains 2579 and 2463) both demonstrated no inhibition zone in the disk diffusion assay (6 mm), suggesting that the combination between the Liofilchem disk with Liofilchem r-MHA could detect cefiderocol-resistant *Achromobacter* strains. Unlike strain 2463, which showed homogeneous resistance (no visible inhibition zone), strain 2579 showed heterogeneous growth (double halo of growth with an outer IZD of 31 mm and no inner inhibition zone) (Supplementary Fig. 3). Strains with cefiderocol MICs below the PK/PD critical concentration value ( $\leq 2$  mg/L) [15] had IZDs systematically  $\geq 27$  mm (range: 27 to 39 mm with no microcolonies in the IZD) around a disk loaded with 30  $\mu$ g cefiderocol.

### MTS

The MIC values for cefiderocol against the quality control strain *P. aeruginosa* (range: 0.19–0.5 mg/L,  $n=5$ ) were within the acceptable range (Supplementary Fig. 1).

Compared with both the ComASP™ and UMIC® assays, MTS was the commercial method that gave the lowest percentage of EA (30.8%,  $n=44/143$ , 95% CI [23.8–38.8]) (Fig. 1; Table 2). Even when considering isolates with a difference from the reference method of up to  $\pm$ three 2-fold dilutions, the modified EA (87.4%,  $n=125/143$ , 95% CI [81–91.9]) did not reach the 90% rate required to consider the method as acceptable, confirming MTS a poorly accurate technique for determining reliable cefiderocol MICs. However, unlike ComASP™ and UMIC®, this method successfully classified both cefiderocol-resistant strains with MICs  $> 256$  mg/L (Fig. 1; Table 2).

### Analysis of discordant results between commercial tests according to strain and species

According to the BMD reference method, the two cefiderocol-resistant strains (strains 2579 and 2463) were both detected as resistant by the diffusion-based methods whereas they were erroneously categorized as susceptible by either one method (UMIC®, strain 2463) or both (ComASP™ and UMIC®, strain 2579) commercial BMD methods. Thus, the use of commercial BMD methods as the sole method for cefiderocol susceptibility testing has to be discouraged for *Achromobacter* spp. to avoid reporting false-susceptible results.


Distribution of the cefiderocol MICs or IZDs according to *Achromobacter* species is shown in Fig. 2. Analysis according to *Achromobacter* species showed that discrepancies in MICs (at least  $\pm$ two 2-fold dilutions) observed between both MTS or UMIC® commercial tests and the BMD reference method were dependent on the species

under study, unlike with ComASP™ ( $p\text{-value}_{\text{MTS}} < 0.001$ ,  $p\text{-value}_{\text{UMIC}^\circ} = 0.002$ ,  $p\text{-value}_{\text{ComASP}^\circ} = 0.3$ ) according to the Fisher test. ComASP™ was the commercial technique with the highest EA for *A. xylosoxidans* (EA=78.5%,  $n=73/93$ , 95% CI [69.1–85.6]) compared to both UMIC® (EA=41.9%,  $n=39/93$ , 95% CI [32.4–52.1]) and MTS (EA=23.7%,  $n=22/93$ , 95% CI [16.2–33.2]), which provided more discordant than concordant MIC results for that species (the most common species recovered from clinical samples worldwide). Note that *A. insolitus* was the only species represented by more than four strains in this study ( $n=5$ ), with 100% EA whatever the commercial technique used.

### Performance of methods in the literature

We found 16 comparative studies including one to four methods for cefiderocol susceptibility testing among disk diffusion, MIC strips, Sensititre EUMDROXF microplates, ComASP™ and UMIC®, mostly compared to the BMD reference method [10, 14, 19–32]. Eleven of these studies included a unique bacterial group [*Acinetobacter baumannii* complex ( $n=6$ ), Enterobacterales ( $n=3$ ), and *P. aeruginosa* ( $n=2$ )] whereas the five remaining studies included three to six bacterial groups, either multidrug-resistant (MDR), carbapenemase-producing or not, among Enterobacterales, *P. aeruginosa*, *A. baumannii* complex, *Stenotrophomonas maltophilia*, *Burkholderia* spp. and *Achromobacter* spp. (Supplementary Table 2). Depending on the method under evaluation, data were available for 38 to 342 Enterobacterales, for 3 to 150 *P. aeruginosa*, for 7 to 468 *A. baumannii* complex, for 10 to 30 *S. maltophilia*, for 30 *Burkholderia* spp. and 27 *Achromobacter* spp. strains. Performance of the different methods are presented in Supplementary Table 2 according to bacterial species or group.

Studies evaluating disk diffusion showed conflicting performance, which depended not only on the bacterial species under study but also on the combination disk/r-MHA selected [10, 14, 19–23, 26–32]. For some studies, the difference in performance also depended on the breakpoints used for categorization [27, 30, 31] (Supplementary Table 2). For Enterobacterales, CAs ranging from 77 to 100% were observed in the eight studies retrieved, and half of them showed insufficient performance with the disk diffusion method (CA  $< 90\%$ ) to assess cefiderocol susceptibility. Only the results obtained with the Mast disks tested on r-MHA showed CA rates that were consistently  $\geq 90\%$  for Enterobacterales [10, 21]. For *P. aeruginosa* (six studies) and *A. baumannii* complex (ten studies), none of the disks tested provided CA rates consistently  $> 90\%$  for all studies. By contrast, studies evaluating the performance of cefiderocol disks on *S. maltophilia* (three studies, 11–30 strains) as well as the only study on a small number of *Burkholderia* spp. and *A.*



**Fig. 2** Distribution of the cefiderocol MICs (mg/L) or IZDs (mm) determined by several methods for 143 *Achromobacter* strains according to species. **(a)** BMD reference method, **(b)** ComASP™, **(c)** UMIC®, **(d)** Liofilchem MTS, **(e)** Liofilchem disks. Disk and MTS assays were performed on unsupplemented MH II agar plates (Liofilchem). BMD: broth microdilution; IZD: inhibition zone diameter; MIC: minimal inhibitory concentration

*xylosoxidans* strains (30 and 27 strains, respectively) suggested that the disk method performed well (CA=100%), irrespective of the disk manufacturer (Liofilchem, Oxoid - Thermo Fisher Scientific or Mast Diagnostic) [10, 20, 21].

Regarding the MTS gradient strip that was formulated for *P. aeruginosa* only, the four studies which had evaluated this method on bacteria other than *P. aeruginosa* found very poor performance with EA ranging from 6% [23] to 75% [30], high biases of up to -48.4% when calculated [30], and unacceptable VME rates confirming that MTS should be avoided for these bacteria (Supplementary Table 2). The use of MTS was also discouraged for *P.*

*aeruginosa* showing insufficient performance (EA=69.3% and bias = -30.4%) [14].

The Sensititre EUMDROXF microplate was evaluated in two studies comparing it with the BMD reference method. The EA and CA rates were higher for Enterobacteriales than for *P. aeruginosa*, for which the method overestimated MIC values. However, both studies showed unacceptably high rates of VME [14, 23] (Supplementary Table 2).

ComASP™ has already been evaluated for Enterobacteriales, *P. aeruginosa* and *A. baumannii* complex strains [20, 24, 29, 30, 32] either as first-line antimicrobial susceptibility method or as second-line on isolates that



presented an IZD within area of technical uncertainty (ATU) using the disk diffusion method. All species considered, performance of the test was not sufficient for use in clinical diagnostics according to the ISO 20776-2:2021 validation criteria (Supplementary Table 2). Indeed, ComASP™ never achieved 90% EA, ranging from a minimum of 29.6% for carbapenem-resistant *Acinetobacter* spp. ( $n=27$ ) [32] to a maximum of 86.8% for carbapenemase-producing Enterobacterales ( $n=38$ ) [20]. In all studies including more than 10 strains, unacceptable VME rates were also observed with this method despite the fact that CA values compared to the BMD reference method ranged from 74.1% for *Acinetobacter* spp. ( $n=27$ ) [32] to 95.9% for the same bacterial genus ( $n=97$ ) [29].

Finally, UMIC® appeared to perform better on *P. aeruginosa* than on Enterobacterales, with acceptable EA, CA and VME rates in the two studies reviewed, despite an unacceptable bias value in one of those two studies [10, 25] (Supplementary Table 2). Contrasting evaluation results have been published for other pathogens. The values of biases varied significantly from one study to another for Enterobacterales and *A. baumannii* complex (Supplementary Table 2) [10, 24, 25, 29]. The two studies on *S. maltophilia* or *Burkholderia* spp. found unacceptable EA and bias rates with an overestimation of the MIC when calculated, but CA rates were  $\geq$  to 90% [10, 25].

## Discussion

Cefiderocol susceptibility testing remains challenging due to technical specificities and the distinct performance of available testing methods depending both on the pathogen and the testing conditions. The reference BMD method for in vitro susceptibility testing of cefiderocol involves a complex and time-consuming preparation of an ID-CAMHB, making this technique inappropriate for routine testing in a clinical microbiology laboratory [11]. Consequently, various commercial systems have been developed for routine cefiderocol susceptibility testing. Agar diffusion methods, using either the disk method or cefiderocol-impregnated strips, which do not require iron-depleted media, and commercial microdilution techniques mimicking the BMD reference method, have become available. However, the performance of these different methods has been found to vary greatly depending on the pathogen tested and, for diffusion assays, according to the testing conditions, as highlighted in our literature review.

### Diffusion assays and the value of disk diffusion for cefiderocol susceptibility testing in the *Achromobacter* genus

Generally speaking, the comparative studies reviewed all agree that determining MICs *via* the MTS assay cannot currently be recommended for cefiderocol susceptibility

testing due to its severe underestimation of the cefiderocol MICs generating unacceptable rates of VME in Enterobacterales and *A. baumannii* complex isolates, bacteria for which the MTS is not validated, but also in *P. aeruginosa* strains, for which the MTS is approved. Our study evaluating MTS on *Achromobacter* spp. strains highlighted, for the first time, that although MTS succeeded in correctly categorizing the two cefiderocol-resistant *Achromobacter* strains, it proved to be inaccurate for cefiderocol MIC determination with a low EA of 30.8% and unacceptable values for high and low biases, +53.8 to -55.1%, respectively. MTS is thus a poor accurate technique for determining reliable cefiderocol MICs and its use must be discouraged, whatever the species under consideration [14, 22, 23, 29, 30, 32]. Some studies consider disk diffusion as a convenient, alternative testing method to BMD for determining cefiderocol susceptibility, but found variable performance according to the bacterial species being studied and the disk/r-MHA combination selected. Altogether, these studies lead to distinct recommendations for both the use of the disk diffusion assay and result interpretation depending on the committee on antimicrobial susceptibility testing under consideration [10, 14, 19–23, 26–32]. Although disk diffusion might be useful for screening, many strains should be re-tested by alternative methods providing MIC results to assess definitive categorization [14, 23].

To date, our study is the only one to have tested the performance of cefiderocol disks on such a wide panel of 143 *Achromobacter* spp. strains assigned to 14 species by *nrdA* gene sequencing and encompassing various sources of isolation. Indeed, the only data available so far on *Achromobacter* spp. are those recently published by Bianco et al. for 27 *A. xylosoxidans* strains, of which six cefiderocol-resistant strains were obtained after in vitro induction from three originally susceptible strains [10]. On that collection tested with disks from three manufacturers (Oxoid, Liofilchem, Mast Group) on the same r-MHA (non-communicated brand), the authors reported a 100% CA rate compared to the BMD reference method whatever the test conditions when using the EUCAST 2023 breakpoints for *P. aeruginosa* (Supplementary Table 2). With a larger, more taxonomically diverse collection of *Achromobacter* strains, including a few cefiderocol-resistant strains, the present study confirmed that the disk diffusion method performs well for *Achromobacter* spp. as it led to the detection of the two resistant strains in the study with the combination of Liofilchem disks and Liofilchem r-MHA. The phenomenon of heterogeneous growth and resistance observed with strain 2579 (found resistant with the BMD reference method) leads us to recommend considering even weak bacterial growth up to contact with the disk: the inner edge of the IZD should be measured in the event of heterogeneous growth [33,

34]. Heteroresistance to cefiderocol, previously reported in other MDR Gram-negative pathogens with debated correlation between heteroresistance and clinical outcomes, is thus also observed in the *Achromobacter* genus and its contribution to cefiderocol treatment failure remains to be evaluated.

Another input of our study was to report the FDC IZD distribution for the collection beyond study, showing that the population susceptible to cefiderocol consistently displayed an  $IZD \geq 27$  mm. However, this result alone cannot be considered as a breakpoint, as our study did not fulfil the EUCAST procedure for establishing zone diameter breakpoints requiring that both several disk and agar medium suppliers be tested in several laboratories [35]. Indeed, although Matuschek et al. showed that the susceptibility results of quality control strains were largely unaffected by the disk and media manufacturers [36], other studies showed large variations in IZDs with clinical strains depending on the disk and r-MHA combinations, notably linked to variable iron concentrations from one batch of r-MHA to another, which may influence cefiderocol susceptibility results [14, 37]. It would thus be interesting to test other combinations of cefiderocol disk and MHA from other manufacturers on our collection of *Achromobacter* spp. strains to go further with a breakpoint proposal. It should be noted that data from the study by Bianco et al. still suggest that the disk manufacturer has a low impact on IZD with a maximum of  $\pm 3$  mm observed between manufacturers (no variation, variations of  $\pm 1$  mm,  $\pm 2$  mm,  $\pm 3$  mm observed for 7.5%, 59.2%, 29.6% and 3.7% of the 27 *A. xylosoxidans* strains tested) [10]. Thus, to generalise a cefiderocol susceptibility threshold for *Achromobacter* when using disk/r-MHA combinations from manufacturers other than Liofilchem, it seems more appropriate to propose a susceptibility threshold of 30 mm (*i.e.* 3 mm beyond the susceptible strain with the lowest IZD measured at 27 mm) above which strains would be susceptible to cefiderocol and below which a determination of the MIC with a BMD method will be required to confirm or exclude cefiderocol resistance. This proposition is congruent with the data published by Bianco et al. showing that the six cefiderocol-resistant induced strains that display IZDs ranging from 6 to 26 mm regardless of the disk brand used [10].

#### Commercial BMD methods and warnings on the non-detection of cefiderocol-resistant *A. xylosoxidans* strains

Sensititre EUMDROXF microplates (Thermo Fisher Scientific, Cleveland, OH, USA) corresponding to cefiderocol pre-coated wells with a specific iron chelator which allowed the use of a standard CAMHB (Thermo Fisher Scientific) without iron depletion, were not evaluated in our study as they were withdrawn from the market in

February 2022 [14]. An excess of free iron in the microplate wells once inoculated with non-ID-CAMHB was suspected to be the cause of MIC overestimation. The issue has not yet been resolved, and this method thus remains to be evaluated on *Achromobacter* spp. strains.

To date, ComASP™ has been evaluated in Enterobacterales, *P. aeruginosa*, *A. baumannii* complex, but never in the *Achromobacter* spp. genus (Supplementary Table 2) [20, 24, 29, 30, 32]. Despite the differences observed among pathogens, performance of the ComASP™ test was insufficient for use in clinical diagnostics according to the ISO 20776-2:2021 validation criteria (Supplementary Table 2). However, in evaluating the performance of the ComASP™ for 50 carbapenemase-producing GNB isolates that presented an IZD within ATU by using the disk diffusion method, Bianco et al. concluded that ComASP™ achieved good performance compared to the BMD reference method with a CA of 94% and both the VME (2.0%) and ME (4.0%) observed for MIC values were nearly close to the resistance breakpoint (2 mg/L) [20]. Thus, the combination of disk diffusion with ComASP™ was shown to be a valid strategy to resolve the susceptibility interpretation of isolates in the ATU and overcome the challenge of routine cefiderocol susceptibility testing in microbiology laboratories.

One limitation of our work is the small number of cefiderocol-resistant isolates ( $n=2$ ) which made it difficult to assess the performance of commercial tests against these rarely isolated strains [2–6, 9, 38, 39]. However, the performance of ComASP™ in *Achromobacter* spp. evaluated here for the time was similar to that published for other bacterial genera. Indeed, this technique failed to detect the two strains resistant to cefiderocol, mainly because the MICs were underestimated (EA=76.9%, bias = -14.2%). In contrast to the diffusion methods, ComASP™ wrongly categorized the only two *Achromobacter* resistant strains in our study as susceptible to cefiderocol, discouraging its use for routine cefiderocol susceptibility testing. Compared with ComASP™, the literature review data showed that UMIC® appears to provide better performance, achieving the acceptable criteria defined by the ISO for both Enterobacterales (EA=91.7%, bias = -10%,  $n=60$  [24] and EA=91.7%, bias = -25%,  $n=180$  [25]) and *P. aeruginosa* (EA=93.9%, bias = +12.2%,  $n=49$  [25]). The UMIC® also appears to perform better than the ComASP™ in *A. baumannii*, with EA ranging from 76% [30] to 89.7% [10] with UMIC®, and 29.6% [32] to 85.7% [20] with ComASP™. All species considered, ComASP™ test tended to provide lower MIC values while the UMIC® tended to provide higher MIC values compared to the BMD reference method that was also observed for the quality control strain *P. aeruginosa* and *Achromobacter* spp. isolates in our study as illustrated by a bias = -14.2% for ComASP™ and a bias = +9.1% for

UMIC<sup>®</sup>. However, poorer overall performance of UMIC<sup>®</sup> were noticed in our study (EA=49%) compared with the only study published by Bianco et al. to date (EA=92.6%, CA=96.2%, VME=16.7%) [10]. Taken together that UMIC<sup>®</sup> successfully classified one of the two *Achromobacter* resistant strains, unlike ComASP<sup>™</sup>, but showed poorer EA (49%) compared to ComASP<sup>™</sup> (76.9%) makes them two equivalent techniques that would be interesting to evaluate on a larger number of cefiderocol-resistant *Achromobacter* strains.

## Conclusion

As cefiderocol is currently unavailable in all commercial automated AST panels [40], commercial tests may be suitable alternative methods for routine testing of *Achromobacter* susceptibility to cefiderocol in microbiology laboratories. To the best of our knowledge, this is the first study to evaluate the performance of disk diffusion, MTS and two BMD commercial tests (ComASP<sup>™</sup> and UMIC<sup>®</sup>) to assess susceptibility to cefiderocol of an accurately identified collection of *Achromobacter* spp. clinical strains, compared to the standard BMD method. This is also the first literature review to summarize the performance of commercially available AST methods for cefiderocol, for all bacterial species.

Although the use of MTS should be discouraged for *Achromobacter* spp. due to the low EA compared with the standard BMD method, the disk diffusion method can be used as a susceptibility screening tool with a cut-off diameter of 30 mm: strains with an IZD $\geq$ 30 mm could be categorized as susceptible to cefiderocol without further testing. However, for strains with an IZD $<$ 30 mm, it would be necessary to determine the MIC of cefiderocol by a BMD method. Commercialized BMD methods, either ComASP<sup>™</sup> or UMIC<sup>®</sup>, should not be used as the sole method for cefiderocol susceptibility testing but have to be systematically associated with a disk diffusion test to detect the yet rarely described cefiderocol-resistant *Achromobacter* sp. strains that could be overlooked by ComASP<sup>™</sup> or UMIC<sup>®</sup>. In case of persisting interpretation difficulties, strains have to be sent to a reference laboratory performing the BMD reference method, as ComASP<sup>™</sup> or UMIC<sup>®</sup> do not meet the acceptable EA as defined by ISO 20776-2:2021, despite showing an acceptable bias  $<\pm 30\%$ .

## Abbreviations

AST	Antimicrobial susceptibility testing
ATU	Area of technical uncertainty
BMD	Broth microdilution
CF	Cystic fibrosis
ComASP <sup>™</sup>	Compact antimicrobial susceptibility panel
EUCAST	European committee on antimicrobial susceptibility testing
GNB	Gram-negative bacilli
ID-CAMHB	Iron-depleted-cation-adjusted Mueller-Hinton broth
IZD	Inhibition zone diameter
r-MHA	Regular Mueller-Hinton-agar
MDR	Multidrug resistant

MEM	Meropenem
MIC	Minimal inhibitory concentration
MTS	MIC gradient test strips
NCF	Non-cystic fibrosis
PK/PD	Pharmacokinetics and pharmacodynamics
TZP	Piperacillin-tazobactam
SXT	Trimethoprim-sulfamethoxazole

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12941-024-00731-1>.

Supplementary Material 1

Supplementary Material 2

Supplementary Material 3

## Acknowledgements

The authors wish to thank Teresa Sawyers, Medical Writer at the B.E.S.P.I.M., Nîmes University Hospital, France, for editing this manuscript, Florian Salipante for his assistance with the statistical analysis and Fabien Aujoulat, Mylène Toubiana, Stefaniya Hantova and Agnès Masnou for their technical assistance. The authors would like to acknowledge colleagues who have provided *Achromobacter* clinical strains: Lucile Cadot (Centre Hospitalier Alès-Cévennes, France), Patricia Mariani-Kurkdjian (Hôpital Universitaire Robert-Debré, Paris, France) and Niels Nørskov-Lauritsen (Aarhus University Hospital, Aarhus, Denmark).

## Author contributions

HM and AP conceived and designed the study. RC, HM collected the CF clinical isolates. AP, JPL, HM collected the non-CF clinical isolates. VJP, PS, KJ and HM collected the microbiological data, analyzed and interpreted the data. VJP and HM drafted the manuscript. All authors read and approved the final manuscript.

## Funding

This work was supported by Shionogi SAS, which provided supplies for cefiderocol susceptibility testing (disk, medium and commercial BMD assays) and for open access fees.

## Data availability

No datasets were generated or analysed during the current study.

## Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Service de Microbiologie et Hygiène hospitalière, HydroSciences Montpellier, Univ. Montpellier, CNRS, IRD, CHU de Nîmes, Montpellier 34093, France

<sup>2</sup>CPIas Loire Atlantique, CHU de Nantes, Nantes 44093, France

<sup>3</sup>Laboratoire associé du Centre National de Référence de la Résistance aux Antibiotiques, CHU de Besançon, Besançon 25000, France

<sup>4</sup>Centre de Ressources et de Compétences de la Mucoviscidose, HydroSciences Montpellier, Univ. Montpellier, CNRS, IRD, CHU de Montpellier, Montpellier 34093, France

<sup>5</sup>Service de Microbiologie et Hygiène hospitalière, VBIC, INSERM U1047, Univ. Montpellier, CHU de Nîmes, Nîmes 30900, France

Received: 5 July 2024 / Accepted: 29 July 2024

Published online: 22 August 2024

## References

- Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18:268–81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
- Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. *Achromobacter* infections and treatment options. *Antimicrob Agents Chemother.* 2020;64:e01025–20. <https://doi.org/10.1128/AAC.01025-20>.
- Warner NC, Bartelt LA, Lachiewicz AM, Tompkins KM, Miller MB, Alby K, et al. Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and *Achromobacter xylosoxidans* infections. *Clin Infect Dis.* 2021;73:e1754–7. <https://doi.org/10.1093/cid/ciaa1847>.
- Gainey AB, Burch A, Brownstein MJ, Brown DE, Fackler J, Horne B, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant *Achromobacter* species infection in a pediatric cystic fibrosis patient. *Pediatr Pulmonol.* 2020;55:2990–4. <https://doi.org/10.1002/ppul.24945>.
- Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. *Ann Intensive Care.* 2023;13:52. <https://doi.org/10.1186/s13613-023-01146-5>.
- Jean-Pierre V, Sorlin P, Pantel A, Chiron R, Lavigne J-P, Jeannot K, et al. Cefiderocol susceptibility of *Achromobacter* spp.: study of an accurately identified collection of 230 strains. *Ann Clin Microbiol Antimicrob.* 2024;23:54. <https://doi.org/10.1186/s12941-024-00709-z>.
- Oueslati S, Bogaerts P, Dortet L, Bernabeu S, Ben Lakhel H, Longshaw C, et al. In vitro activity of cefiderocol and comparators against carbapenem-resistant Gram-negative pathogens from France and Belgium. *Antibiotics.* 2022;11:1352. <https://doi.org/10.3390/antibiotics11101352>.
- Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of cefiderocol and comparators against isolates from cancer patients. *Antimicrob Agents Chemother.* 2020;64:e01955–19. <https://doi.org/10.1128/AAC.01955-19>.
- Takemura M, Nakamura R, Ota M, Nakai R, Sahn DF, Hackel MA, et al. In vitro and in vivo activity of cefiderocol against *Achromobacter* spp. and *Burkholderia cepacia* complex, including carbapenem-non-susceptible isolates. *Antimicrob Agents Chemother.* 2023:e00346–23. <https://doi.org/10.1128/aac.00346-23>.
- Bianco G, Boattini M, Comini S, Gaibani P, Cavallo R, Costa C. Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Achromobacter xylosoxidans* and *Burkholderia* species. *Eur J Clin Microbiol Infect Dis.* 2024;43:559–66. <https://doi.org/10.1007/s10096-024-04745-7>.
- Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowitsch JA, Sahn DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. *Diagn Microbiol Infect Dis.* 2019;94:321–5. <https://doi.org/10.1016/j.diagmicrobio.2019.03.003>.
- Sorlin P, Brivet E, Jean-Pierre V, Aujoulat F, Besse A, Dupont C, et al. Prevalence and variability of siderophore production in the *Achromobacter* Genus. *Microbiol Spectr* 2024;12:e02953–23. <https://doi.org/10.1128/spectrum.02953-23>.
- EUCAST. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_14.0\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf); 2024 [accessed 24 May 2024].
- Devoos L, Biguenet A, Rousselot J, Bour M, Plésiat P, Fournier D, et al. Performance of discs, sensititre EUMDROX microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant *Pseudomonas aeruginosa* to cefiderocol. *Clin Microbiol Infect.* 2023;29:652e1. <https://doi.org/10.1016/j.cmi.2022.12.021>.
- EUCAST. Available online: [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/v\\_13.1\\_Breakpoint\\_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf); 2023 [accessed 24 May 2024].
- Clinical laboratory testing, and *in vitro* diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 2: evaluation of performance of antimicrobial susceptibility test devices against reference broth micro-dilution (ISO 20776–2:2021). ITH Standards. <https://standards.iteh.ai/catalog/standards/cen/92fc193a-5135-4d74-b3b5-a6962a16e505/en-iso-20776-2-2022>.
- Clinical laboratory testing, and *in vitro* diagnostic test systems-susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 2: evaluation of performance of antimicrobial susceptibility test devices (ISO 20776–2:2007). ITH Standards. <https://standards.iteh.ai/catalog/standards/cen/e58114a5-4af0-488d-addf-f410a8445ee0/en-iso-20776-2-2007>.
- The European Committee on Antimicrobial Susceptibility Testing. EUCAST Warnings. Available online: <https://www.eucast.org/ast-of-bacteria/warnings> (accessed on 26 May 2024).
- Nayak G, Behera B, Mohanty S, Kar P, Jena J. Analysis of *in vitro* activity of cefiderocol against carbapenem-resistant Gram-negative bacilli by broth microdilution and disk diffusion method: a single-center study in Odisha, India. *IDR* 2022;Volume 15:5887–97. <https://doi.org/10.2147/IDR.S378579>.
- Bianco G, Boattini M, Comini S, Banche G, Cavallo R, Costa C. Disc diffusion and ComASP® cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine. *Antibiotics.* 2023;12:604. <https://doi.org/10.3390/antibiotics12030604>.
- Morris CP, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simmer PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. *J Clin Microbiol.* 2020;59:e01649–20. <https://doi.org/10.1128/JCM.01649-20>.
- Bovo F, Lazzarotto T, Ambretti S, Gaibani P. Comparison of broth microdilution, disk diffusion and strip test methods for cefiderocol antimicrobial susceptibility testing on KPC-producing *Klebsiella pneumoniae*. *Antibiotics.* 2023;12:614. <https://doi.org/10.3390/antibiotics12030614>.
- Bonnin RA, Emeraud C, Jousset AB, Naas T, Dortet L. Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales. *Clin Microbiol Infect.* 2022;28. <https://doi.org/10.1016/j.cmi.2022.04.013>. :1156.e1-1156.e5.
- Emeraud C, Gonzalez C, Dortet L. Comparison of ComASP® and UMIC® methods with the reference method for cefiderocol susceptibility testing on carbapenem-resistant Enterobacterales. *J Antimicrob Chemother.* 2023;78:1800–1. <https://doi.org/10.1093/jac/dkad134>.
- Dortet L, Niccolai C, Pfennigwerth N, Frisch S, Gonzalez C, Antonelli A, et al. Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria. *J Antimicrob Chemother.* 2023;78:1672–76. <https://doi.org/10.1093/jac/dkad149>.
- Kufel WD, Steele JM, Riddell SW, Jones Z, Shakeraneh P, Endy TP. Cefiderocol for treatment of an empyema due to extensively drug-resistant *Pseudomonas aeruginosa*: clinical observations and susceptibility testing considerations. *IDCases.* 2020;21:e00863. <https://doi.org/10.1016/j.idcr.2020.e00863>.
- Liu Y, Ding L, Han R, Zeng L, Li J, Guo Y, et al. Assessment of cefiderocol disk diffusion versus broth microdilution results when tested against *Acinetobacter baumannii* complex clinical isolates. *Microbiol Spectr.* 2023;11:e05355–22. <https://doi.org/10.1128/spectrum.05355-22>.
- Carcione D, Siracusa C, Sulejmani A, Migliavacca R, Mercato A, Piazza A, et al. In vitro antimicrobial activity of the siderophore cephalosporin cefiderocol against *Acinetobacter baumannii* strains recovered from clinical samples. *Antibiotics.* 2021;10:1309. <https://doi.org/10.3390/antibiotics10111309>.
- Jeannot K, Gaillot S, Triponney P, Portets S, Pourchet V, Fournier D, et al. Performance of the disc diffusion method, MTS gradient tests and two commercially available microdilution tests for the determination of cefiderocol susceptibility in *Acinetobacter* spp. *Microorganisms.* 2023;11:1971. <https://doi.org/10.3390/microorganisms11081971>.
- Kolesnik-Goldmann N, Seth-Smith HMB, Haldemann K, Imkamp F, Roloff T, Zbinden R, et al. Comparison of disk diffusion, E-test, and broth microdilution methods for testing in vitro activity of cefiderocol in *Acinetobacter baumannii*. *Antibiotics.* 2023;12:1212. <https://doi.org/10.3390/antibiotics12071212>.
- Uskudar-Guclu A, Danyildiz S, Mirza HC, Akcil Ok M, Basustaoglu A. In vitro activity of cefiderocol against carbapenem-resistant *Acinetobacter baumannii* carrying various β-lactamase encoding genes. *Eur J Clin Microbiol Infect Dis.* 2024;43:1171–9. <https://doi.org/10.1007/s10096-024-04831-w>.
- Pasteran F, Wong O, Mezcord V, Lopez C, Georgeos N, Fua V, et al. Comparison of available methods to evaluate cefiderocol susceptibility in *Acinetobacter* Spp. *J Microbiol Methods* 2024;223:106972. <https://doi.org/10.1016/j.mimet.2024.106972>.
- Choby JE, Ozturk T, Satola SW, Jacob JT, Weiss DS. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. *Lancet Infect Dis.* 2021;21:597–8. [https://doi.org/10.1016/S1473-3099\(21\)00194-8](https://doi.org/10.1016/S1473-3099(21)00194-8).
- Longshaw C, Santerre Henriksen A, Dressel D, Malysa M, Silvestri C, Takemura M, et al. Heteroresistance to cefiderocol in carbapenem-resistant *Acinetobacter baumannii* in the CREDIBLE-CR study was not linked to clinical outcomes: a *post hoc* analysis. *Microbiol Spectr.* 2023;11:e02371–23. <https://doi.org/10.1128/spectrum.02371-23>.

35. European Committee on Antimicrobial Susceptibility Testing. Procedure for establishing zone diameter breakpoints and quality control criteria for new antimicrobial agents. EUCAST SOP9.3, 2022. [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/EUCAST\\_SOPs/2022/EUCAST\\_SOP\\_9.2\\_Disk\\_diffusion\\_breakpoints\\_and\\_QC\\_ranges\\_final\\_20200721.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/2022/EUCAST_SOP_9.2_Disk_diffusion_breakpoints_and_QC_ranges_final_20200721.pdf)
36. Matuschek E, Longshaw C, Takemura M, Yamano Y, Kahlmeter G, Cefiderocol. EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing. *J Antimicrob Chemother.* 2022;77:1662–9. <https://doi.org/10.1093/jac/dkac080>.
37. Potter RF, Wallace MA, Muenks CE, Alvarado K, Yarbrough ML, Burnham C-AD. Evaluation of variability in interpretation of disk diffusion testing for cefiderocol using different brands of Mueller-Hinton agar. *J Appl Lab Med.* 2023;8:523–34. <https://doi.org/10.1093/jalm/jfac131>.
38. Beauruelle C, Lamoureux C, Mashi A, Ramel S, Le Bihan J, Ropars T, et al. In vitro activity of 22 antibiotics against *Achromobacter* isolates from people with cystic fibrosis. Are There New Therapeutic Options? *Microorganisms.* 2021;9:2473. <https://doi.org/10.3390/microorganisms9122473>.
39. Larcher R, Laffont-Lozes P, Roger C, Doncesco R, Groul-Viaud C, Martin A, et al. Last resort beta-lactam antibiotics for treatment of New-Delhi metallo-beta-lactamase producing enterobacterales and other difficult-to-treat resistance in Gram-negative bacteria: a real-life study. *Front Cell Infect Microbiol.* 2022;12:1048633. <https://doi.org/10.3389/fcimb.2022.1048633>.
40. Gijón CD, Castillo-Polo JA, Ruiz-Garbajosa P, Cantón R. Antibacterial spectrum of cefiderocol. *Rev Esp Quimioter.* 2022;35:20–7. <https://doi.org/10.37201/req/s02.03.2022>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.